Key Takeaway: Dr. Andrew Conrad has joined Immuneering, bringing over 13 years of experience in analytical, formulation, and manufacturing process development. He previously held significant roles at Hikma Pharmaceuticals, where he led product development, and at Boehringer Ingelheim. Dr. Conrad holds a B.S. in Chemistry and a Ph.D. in Physical Chemistry from Kent State University.
Price reaction · baseline $6.73 (2025-12-26 close) · 13 other IMRX headline(s) in the window, move may be shared
day 0 close · peak
-1%
Market Sentiment Analysis
POSITIVE FACTORS
Dr. Conrad has extensive experience in analytical and formulation development.
He has a strong background in leading product development teams.
His academic credentials include a Ph.D. in Physical Chemistry.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
11.4%
average across 8 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
IMM-1-104 Monotherapy
Phase 1 · Advanced Solid Tumor
Full Press Release Details
Dr. Conrad has over 13 years of experience in analytical, formulation, and manufacturing process development. Prior to joining Immuneering in April 2025, Dr. Conrad held roles of increasing responsibility at Hikma Pharmaceuticals developing generic injectable medicines culminating in his leadership of an integrated group responsible for end-to-end product development. He also worked previously for Boehringer Ingelheim in R&D and Operations. Dr. Conrad received his B.S. in Chemistry and his Ph.D. in Physical Chemistry from Kent State University.
Frequently Asked Questions
What is Dr. Andrew Conrad's background?
Dr. Conrad has over 13 years of experience in analytical and formulation development.
Where did Dr. Conrad work before Immuneering?
He previously worked at Hikma Pharmaceuticals and Boehringer Ingelheim.
What degrees does Dr. Conrad hold?
He holds a B.S. in Chemistry and a Ph.D. in Physical Chemistry.
What role did Dr. Conrad have at Hikma Pharmaceuticals?
He led an integrated group responsible for end-to-end product development.